Enliven Therapeutics Inc. (ELVN) Insider Trading
Total insider buys:
- $0.00
Total insider sells:
- $60,397,719.88
Most recent insider trade:
- Aug. 27, 2025
Most active insider trader:
- Benjamin Hohl
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| April 1, 2024 | insider | 12,000 | $18.60 | Sell | $223,200.00 | |
| March 27, 2024 | CFO | 3,250 | $18.25 | Sell | $59,312.50 | |
| March 25, 2024 | CEO | 12,000 | $17.56 | Sell | $210,720.00 | |
| March 19, 2024 | Director | 1,270 | $14.50 | Sell | $18,415.00 | |
| March 6, 2024 | COO | 4,875 | $15.64 | Sell | $76,245.00 | |
| Feb. 29, 2024 | insider | 12,000 | $16.42 | Sell | $197,040.00 | |
| Feb. 27, 2024 | CFO | 3,250 | $16.97 | Sell | $55,152.50 | |
| Feb. 15, 2024 | Director | 1,270 | $17.42 | Sell | $22,123.40 | |
| Feb. 6, 2024 | COO | 4,875 | $15.11 | Sell | $73,661.25 | |
| Jan. 31, 2024 | Major Shareholder | 500,000 | $15.00 | Sell | $7,500,000.00 | |
| Jan. 30, 2024 | Director | 1,270 | $16.41 | Sell | $20,840.70 | |
| Jan. 29, 2024 | insider | 12,000 | $15.85 | Sell | $190,200.00 | |
| Jan. 29, 2024 | CFO | 3,250 | $15.81 | Sell | $51,382.50 | |
| Jan. 25, 2024 | CEO | 12,000 | $15.69 | Sell | $188,280.00 | |
| Jan. 22, 2024 | COO | 4,875 | $15.13 | Sell | $73,758.75 | |
| Jan. 2, 2024 | COO | 11,000 | $15.00 | Sell | $165,000.00 | |
| Jan. 2, 2024 | CFO | 9,383 | $15.01 | Sell | $140,838.83 | |
| Dec. 26, 2023 | CEO | 12,000 | $14.64 | Sell | $175,680.00 | |
| Dec. 26, 2023 | COO | 102 | $15.01 | Sell | $1,531.02 | |
| Dec. 26, 2023 | CFO | 100 | $15.00 | Sell | $1,500.00 | |
| Dec. 22, 2023 | COO | 983 | $15.03 | Sell | $14,774.49 | |
| Dec. 22, 2023 | CFO | 1,030 | $15.07 | Sell | $15,522.10 | |
| Dec. 22, 2023 | CEO | 8,175 | $13.05 | Sell | $106,683.75 | |
| Dec. 21, 2023 | Director | 7 | $13.00 | Sell | $91.00 | |
| Dec. 21, 2023 | insider | 20 | $13.00 | Sell | $260.00 | |
| Dec. 20, 2023 | CEO | 7,779 | $13.01 | Sell | $101,204.79 | |
| Dec. 19, 2023 | insider | 200 | $13.00 | Sell | $2,600.00 | |
| Dec. 19, 2023 | Director | 255 | $13.00 | Sell | $3,315.00 | |
| Nov. 3, 2023 | insider | 8,546 | $13.08 | Sell | $111,781.68 | |
| Nov. 3, 2023 | CEO | 8,026 | $13.08 | Sell | $104,980.08 | |
| Sept. 29, 2023 | insider | 12,000 | $13.62 | Sell | $163,440.00 | |
| Sept. 26, 2023 | Major Shareholder | 197,500 | $15.00 | Sell | $2,962,500.00 | |
| Sept. 25, 2023 | CEO | 12,000 | $13.81 | Sell | $165,720.00 | |
| Aug. 24, 2023 | Major Shareholder | 440,000 | $16.00 | Sell | $7,040,000.00 |
Insiders are selling Enliven Therapeutics Inc. stock.
The insider traders at Enliven Therapeutics Inc. are: Benjamin Hohl, Samuel Kintz, Anish Patel, Joseph P Lyssikatos, Richard A Heyman, Joseph P. Lyssikatos, Rahul D Ballal, 5Am Partners Vi, Llc, and Rishi Gupta
The most active insider trader at Enliven Therapeutics Inc. is Benjamin Hohl with 36 trades.
Rishi Gupta has sold the most Enliven Therapeutics Inc. stock with a total value of $45,754,524.00.
The most recent insider trade for Enliven Therapeutics Inc. was on Aug. 27, 2025.
The single biggest insider sell for Enliven Therapeutics Inc. was from Rishi Gupta with a total value of $22,877,262.00 on May 16, 2024.